Skip to main content

URMC Logo

URMC / Center for AIDS Research / Funding Opportunities / Supplement Award Program

Supplement Award Program

Current Funding Opportunities

There are no current supplement funding opportunities. Please check back regularly.

Past Funding Opportunities

HIV/AIDS Related Malignancies

Stimulates research on HIV-associated malignancies to foster multidisciplinary collaborations between Cancer and CFAR investigators by supporting one-year pilot research projects in HIV-associated malignancies. Pilot studies may include basic, translational, and clinical research on the etiology, pathogenesis, prevention, and management of AIDS-defining and non-AIDS-defining malignancies.

HIV-TB Co-infection

Supports a broad range of highly innovative research on: the alterations in HIV pathogenesis and the host immune response in the setting of TB co-infection; TB related immune reconstitution inflammatory syndrome (IRIS); the effect of TB on HIV clinical disease progression, and changes in latent TB activation and/or active disease progression in the setting of antiretroviral therapy.

Nanotechnology and HIV

Supports a broad range of highly innovative, nanotechnology-based research projects in the field of HIV and HIV-related co-infections such as tuberculosis and hepatitis. Technologies to prevent transmission or acquisition of HIV, improve treatment of HIV and its co-infections, and ultimately cure HIV infection are of particular interest.

HIV and Aging

The goal of this funding opportunity is to improve medical outcomes, functional status and quality of life in older patients with HIV/AIDS through improved understanding of interactions among aging processes, HIV viral infection, treatment effects and toxicities, and multiple morbidities commonly occurring in older persons.

HIV Vaccine Discovery

Supports a broad range of highly innovative research in HIV vaccine discovery, including novel assay/technology development, immunology, virology, cellular and structural biology and host genetics, and novel concepts and approaches applicable to the design of an effective prophylactic HIV vaccine.

Outside the Box AIDS Vaccine Award

Stimulates the discovery, design and preclinical evaluation of highly innovative approaches that could provide long-term protection from acquiring HIV infection. Applicants are expected to explore novel hypotheses or address difficult problems, the solutions to which could have a significant impact on finding methods to interrupt HIV transmission.

HIV Treatment Cascade

The goal of this funding is to enhance efforts around the National HIV AIDS Strategy with an emphasis on building collaborations with health departments, identifying community needs, prioritizing research directions, and conducting formative research relevant to the treatment cascade.  These projects were especially focused on factors associated with linkage to HIV care, engagement, and retention in part to identify targets for intervention.

International Research Career Development

One mission of the CFAR program is to strengthen capacity for HIV/AIDS research in developing countries.  CFARs are encouraged to submit an application to support research career development of junior faculty at institutions in Low and Middle-Income country institutions (LMIC), per World Bank classification, who have on-going research collaborations with CFAR investigators.

HIV-HCV Co-infection

The purpose of these administrative supplements is to support highly innovative research on the effects of HIV infection on hepatitis C virus (HCV) infection or hepatocellular carcinoma (HCC) throughout the clinical spectrum of HCV infection and disease.

Sexual Violence and Biomedical HIV Risk

The biomedical impact of sexual violence is understudied. Understanding the relationship between sexual violence and biomedical HIV risk could provide important information about HIV mucosal transmission and assist biomedical HIV prevention efforts.

The Intersection of HIV Infection and the Human Microbiome

The microbiome is involved in many aspects of health and disease.  It has been shown to play a role in host immunity, and gut homeostasis and has been implicated in several disease including diabetes, colitis, and cancer.  There is a great likelihood that it also has a profound effect on HIV pathogenesis including HIV risk, disease progression, host immune responses, therapeutic uptake and pharmacologic efficacy.

PK Interactions Between ARVs and Other Drugs

The drug–drug interactions between antiretroviral drugs and other types of drugs are important in determining the appropriate drug combinations and dosages for these patients.  This supplement topic requests studies investigating the pharmacology and potential drug-drug interactions across the spectrum of co-morbid conditions.  Supplement requests may incorporate genomics, pharmacogenomics, proteomics, cell biology and metabolomics approaches.

Improve HIV Care Continuum Outcomes

The goal of this funding is to enhance efforts around the National HIV AIDS Strategy with an emphasis on building collaborations with health departments, identifying community needs, prioritizing research directions, and conducting formative research that targeted the HIV treatment cascade.  Projects were encouraged that focused on factors associated with linkage to HIV care, engagement, and retention - in part to inform intervention development. The project must include an academic and public health department partnership and should reflect local community needs as identified by the science and service partners.

Advancing PrEP Delivery

Oral HIV antiretroviral pre-exposure prophylaxis (PrEP) confers a strong preventive benefit to individuals who are at-risk for HIV infection when taken with high adherence. PrEP uptake has been slow, and research is needed to better understand the multi-level factors that may influence PrEP uptake and effective use.  Formative research is encouraged to inform better targeting, engagement, and retention of the highest-risk populations in PrEP care. Novel approaches designed to identify appropriate individuals for PrEP and improve understandings of risk perceptions and decision-making could improve PrEP uptake. Models for retention of individuals in all facets of PrEP care will need to be explored in a variety of potential settings. Effective support for adherence and persistence are also critical to maximizing the preventive benefits of oral PrEP.

HIV Transmission and Microepidemics

The scientific objective of this supplement is to stimulate cross-disciplinary collaborations to identify and target the key microepidemics within high prevalence areas, with the overarching goal to lower HIV prevalence and incidence. Because considerable data are collected in the research and public health spheres, investigators are encouraged to work with their relevant public health agencies to expand the breadth of data available on their local epidemic.

Projects that Highlight the Value Added from Inter-CFAR Collaborations

The idea behind this supplement topic is to request supplements from members of these inter-CFAR collaborations that support some research project that will provide value added to the inter-CFAR group and build on ongoing group collaborations. The proposed work has to include investigators from at least two or more CFARs that are members of the group. The supplement should be driven by a research project.  Each supplement request requires that investigators from at least two different CFARs be involved in the supplement application.

Glycomics in HIV Co-Morbidities

The scientific objective of this supplement is to stimulate novel areas of research in glycomics of HIV associated co-morbidities by supporting pilot and preliminary investigations. Cross-disciplinary research collaboration is needed between HIV researchers, glycobiologists and other relevant disease researchers to effectively formulate questions and to carry out proposed research in this area.  Collaborations between CFAR investigators within the various CFAR working groups such as CNICS and iCHARM and glycobiologists such as investigators that are a part of the consortium for glycomics are encouraged.

Tracking HIV Transmission Phylodynamics: Leveraging Collaborations with Public Health Departments and Others to Research Methods to Analyze Phylogenetic Data in Close to Real-Time

The goal is to develop strategies to identify HIV transmission networks in close to real-time using phylodynamic tracking and modeling.  The objective of the supplement request is to support interdisciplinary collaborations with groups that maintain HIV sequence databases (e.g., public health departments, CDC or testing labs) to study and optimize approaches for using phylodynamic analyses of HIV sequence databases in close to real-time. This will enable more precise tracking of HIV transmission and targeting of prevention and treatment efforts. These studies should have a clear description of the public health implication and impact.

HIV and Host Factor Targets for Structural Research

The objective of this supplement is to enable the characterization and preparation of host and/or viral factor complexes for structural analysis.  A necessary component of this objective is the identification of targets in consultation with a structural biologist with the necessary expertise to guide the development of the target for analysis, since groups with the skills to identify and validate potential targets may lack the knowledge necessary to prepare suitable samples.  The goal for a successful project would be for the awardee to have advanced their target of interest at least to the point just shy of actual high resolution data collection.  This would typically entail not only structurally tractable samples, but also preliminary low resolution structural data indicating the samples are of sufficient quality.  Such low resolution data could include electron microscopy, SAXS, or even preliminary crystallographic data.

Advancing PrEP Delivery

Formative research is encouraged to inform better targeting, engagement, and retention of the highest-risk youth populations in PrEP care. Novel approaches designed to identify appropriate individuals for PrEP, especially youth who are minors and may be hidden from common venues of congregation of older youth, and to improve understandings of risk perceptions and decision-making that could improve PrEP uptake. Models for linkage to and retention of individuals in all facets of PrEP care will need to be explored in a variety of potential settings (e.g. school-based clinics, community health centers, juvenile justice, and etc.). It is expected that applicants will have ongoing affiliations in such settings.  Effective support for consistent high-level adherence is also critical to maximizing the preventive benefits of oral PrEP.

Rapid HIV Treatment Initiation: Implementation Models, Uptake, and HIV Care Continuum Outcomes

This proposed supplemental topic would encourage CFAR investigators to form partnerships in different types of settings where more rapid HIV treatment initiation could be explored. It is not known what elements of these early programs have contributed to their success, and would be essential for launch in other cities, settings, and countries. More research is needed to understand the impact of such programs on HIV care continuum outcomes.

Drug-Drug Interactions in the Context of Antiretroviral Treatment and HIV Co-Infections and Comorbidities

The proposed initiative will support high priority basic or clinical research that focuses on drug-drug interactions between antiretrovirals and drugs used to treat comorbidities (e.g. cancer, diabetes, cardiovascular disease)  or coinfections (e.g. TB, HCV) in HIV-positive populations of various ages in domestic and/or international settings with or without co-occurring substance abuse. 

Active Supplement Awards

Krupa Shah Krupa Shah,
Medicine, Geriatrics

Physical Frailty and Sarcopenia in HIV/AIDS Older Adults (HIV and Aging)

Andrea Sant Andrea Sant,
Center for Vaccine Biology and Immunology

Design of optimal multi-epitope vaccines to elicit CD4 T cell immunity to HIV (HIV Vaccine Discovery)

Steve Gill Steve Gill,
Microbiology and Immunology

Oral Cavity Squamous Cell Carcinoma and Oral Microbiota in HIV-Positive Individuals (HIV/AIDS Related Malignancies)

Photo of Tinashe MudzvitiTinashe Mudzviti
Pharmacist, Zimbabwe AIDS Care Foundation/Newlands Clinic
Neonatal hair measurements to evaluate in-utero tenofovir exposure (International Career Research Supplement)

Photo of Theresa SennTheresa Senn
School of Nursing (November 2014)
Development of a Technology-Based Intervention to Enhance Retention in HIV Care (HIV Cascade)

Hilliard KutscherHilliard Kutscher
Institute of Lasers, Photonics and Biophotonics, SUNY Buffalo
Pharmacokinetics and Immunodynamics of Multi-Model Nanoparticles for TB (HIV-TB Co-Infection)

Matthew DelisaMatthew P. DeLisa
William L. Lewis Professor of Engineering, Chemical and Biomolecular Engineering, Cornell University
TACA-specific antibodies for Comparing Glycan Biomarkers in HIV Comorbidities (Glycomics in HIV Co-Morbidities)

Elizabeth ReddyElizabeth Asiago Reddy
SUNY Upstate Medical University, Syracuse, NY
Discrete Choice Experiments for PrEP Uptake in Young Men Who have Sex With Men (Advancing PrEP Delivery)

Charles VenutoCharles Venuto
Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester
Pharmacokinetics of Methadone in HIV/HCV Infected Patients with and without Liver Fibrosis (Drug-Drug Interactions in the Context of Antiretroviral Treatment and HIV Co-Infections and Comorbidities)